GNI Group to Acquire Ayumi Pharmaceutical Holdings from Blackstone for About ¥44.8 Billion
June 8, 2026
GNI Group Co., Ltd. agreed to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone for an enterprise value of about ¥44.8 billion. The acquisition will make Ayumi a wholly owned subsidiary of GNI and expand GNI’s commercial presence in Japan, particularly in pain management, rheumatology, and related therapeutic areas.
- Buyers
- GNI Group Co., Ltd., Blackstone (as new shareholder in GNI Group post-deal)
- Targets
- Ayumi Pharmaceutical Holdings Co., Ltd.
- Sellers
- Shareholders led by Blackstone
- Industry
- Healthcare Services
- Location
- Tokyo, Japan
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Harbin Pharmaceutical Group Acquires GNC Holdings for $1.2 Billion
April 20, 2026
Healthcare Services
Sycamore Partners has sold GNC Holdings, the distressed vitamin retailer it acquired out of bankruptcy in 2021, to China’s Harbin Pharmaceutical Group for $1.2 billion in cash. The deal is expected to close in Q3 2026, subject to regulatory approval, including CFIUS review.
-
GE HealthCare Acquires Remaining 50% Stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical
March 31, 2025
Healthcare Services
GE HealthCare agreed to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) by purchasing it from Sumitomo Chemical, subject to regulatory approvals. The transaction gives GE HealthCare full ownership of NMP, strengthening its Pharmaceutical Diagnostics and molecular imaging footprint in Japan and for global innovators.
-
Bain Capital to Acquire Mitsubishi Tanabe Pharma in $3.3B Carve-Out
February 7, 2025
Pharmaceuticals
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal values Tanabe Pharma at approximately 510 billion JPY (~$3.3 billion) and is expected to close in the third quarter of 2025, subject to regulatory clearance and approvals.
-
Shin Nippon Biomedical Laboratories Acquires Satsuma Pharmaceuticals
April 16, 2023
Biotechnology
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) has entered into a definitive agreement to acquire all outstanding shares of Satsuma Pharmaceuticals for $0.91 per share in cash plus a non-tradeable contingent value right (CVR) of up to $5.77 per share tied to future monetization of STS101. The transaction gives SNBL ownership of Satsuma's investigational intranasal migraine product STS101 and associated delivery technology, and is supported by Satsuma’s board as maximizing value for stockholders.
-
Amare Global Acquires Kyäni, Inc.
September 20, 2022
Consumer Products
Amare Global has acquired Kyäni, Inc., a global health and wellness company known for its nutritional supplement portfolio and direct-selling distributor network. The deal brings Kyäni founders and certain family shareholders into Amare as shareholders and board representation, and is intended to accelerate Amare's global expansion and product offering.
-
Asahi Kasei Medical to Acquire Bionova Scientific
April 14, 2022
Healthcare Services
Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.